THE COMPANY/THE MISSION
In 2010, Drs. Christopher Burns, Daniel Pevear, and Luigi Xerri set out to build a company focused on anti-infectives; they named it Venatorx, which loosely translated means “Drug Hunter.”
Venatorx’s lead clinical-stage antibiotics address the growing problem of antibiotic resistance.
We continue to explore the company’s pipeline in this next segment on Penicillin Binding Protein Inhibitors.
On day three of this series, we focus on the company’s antiviral program targeting chronic Hepatitis B virus.
Venatorx CEO Christopher Burns talks about the company’s combination therapies in development, its success at advancing its pipeline with non-dilutive funding, and more.
As May’s Company to Watch program concludes, Big4Bio shares thoughts from Venatorx’s Founder and SVP, Biology and Grants Development, Daniel Pevear, Ph.D., about why Venatorx is a company worth watching.
Venatorx Pharmaceuticals’ board member, Vincent Milano, talks about Venatorx’s unique business model, its robust and innovative R&D engine, and more.
To learn more about being a feature company or partner of the Company to Watch program, contact us at firstname.lastname@example.org.